Table of Contents
Metal-Based Drugs
Volume 4, Issue 1, Pages 9-18

Antitumour Activity of a pt(III) Derivative of 2-Mercaptopyrimidine

1Departament de Química Inorgànica, Avgda Diagonal, 647, Barcelona E-08028, Spain
2Departament de Microbiología, Universitat de Barcelona, Avgda Diagonal, 645, Barcelona E-08028, Spain

Received 3 January 1997; Accepted 21 January 1997

Copyright © 1997 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The complex [Pt2Cl2(Spym)4], where Spym = 2-mercaptopyrimidine, was synthesized and analyzed spectroscopically. The presence in the P195t NMR spectrum, of only one signal for the Pt(III) indicates the symmetrical arrangement of the ligands and the identical setting of N, S and Cl atoms, PtS2ClN2, for the two Pt atoms being different to other compounds described in the literature. The interaction of this complex with DNA was studied by several techniques, including circular dichroism, melting temperature determination, electron microscopy (EM) and atomic force microscopy (TMAFM). Preliminary results show a high activity against HL-60 and HeLa tumour lines for the Pt-2-mercaptopyrimidine complex in comparison with cisplatin activity. Higher values for IC50 were obtained, while the values of LD50 were lower than those for cisplatin.